11/25/11 Contest Update
Despite the dismal mood on Wall Street, Gilead’s buyout offer for Pharmasset at a hefty premium was enough to propel the Nasdaq Biotech Index back in the black. And the buyout gave the Contest a new king!
At Friday’s close, the NBI was up 2.30% YTD (vs. down -1.23% YTD a week ago) and the Contest median was down -12.32% YTD (vs. down -9.49% YTD a week ago). The Nasdaq Composite Index was down -7.97% YTD (vs. down -3.03% YTD a week ago).
Strapped to the VRUS rocket, MCBIO’s portfolio (up 59.40% YTD) blasted into the Contest lead, with JIBAC’s portfolio (up 49.15% YTD) now in second place and ROCKY’s’s portfolio (up 33.90% YTD) holding on to third place.
At Friday's close, a mere 9 of the 38 Contest portfolios were in the black, while the same 9 were beating the NBI.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week (foreign stock prices are not converted to US$ in these two tables).
Portfolio adjustments: None
Have a terrific weekend biotechies!
(All corrections, especially adjustments for splits, greatly appreciated.)
11/25/11
Rank Name Profit/Loss
1 MCBIO 59,402
2 JIBAC 49,153
3 ROCKY 33,901
4 FIB 21,854
5 RRGE 16,751
6 GENE 15,725
7 JULIUS 7,473
8 IJF 3,482
9 WILDER 2,906
10 BIOFISH -1,963
Week's Top 5 Gainers
Symbol 11/18 11/25 % change
VRUS 72.67 133.17 83.25%
LPTN.OB 0.91 1.15 26.37%
ABLX.BR 2.25 2.45 8.89%
REGN 49.81 53.78 7.97%
CBPO 7.03 7.49 6.54%
Week's Top 5 Losers
Symbol 11/18 11/25 % change
ROSG 0.42 0.22 -47.62%
NRGXE.OB 0.14 0.09 -35.71%
FOLD 2.77 2.10 -24.19%
YMI 1.65 1.35 -18.18%
PGNX 6.09 5.03 -17.41% |
